. Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis 2024 Apr 27:izae096. doi: 10.1093.
PMID: 38676912